FDA's Fears Realized: Sponsors Pitching Investors 'Sarepta Model'

Investor compares the development construct to homeopathic medicine.

The ink on FDA's controversial approval of Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy drug Exondys 51 has not been dry long, yet other sponsors already want to employ the company's development model.

The emerging trend worries Peter Kolchinsky, managing director of RA Capital Management, who said some companies believe that there is...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet